Skip to content

Accurate, Actionable, and Affordable

Early Cancer Diagnostic Tests

MiRXES’ microRNA-centric liquid biopsy tests complement existing standard diagnostics to enable non-invasive cancer screening and early detection so that timely, life-saving care can be provided to patients.

GASTROClear

The world’s first approved* microRNA blood test for early detection of gastric cancer.

* CE IVD marked and approved for IVD use by Singapore’s Health Sciences Authority.

MiRXES GASTROClear is a qPCR-based diagnostic test kit that measures 12 microRNA biomarkers linked to gastric cancer and calculates a cancer risk score for each patient using a proprietary algorithm that has been clinically validated. 

The test was  developed by MiRXES in collaboration with the Singapore Gastric Cancer Consortium (SGCC), the Diagnostic Development (DxD) Hub of Singapore’s Agency for Science, Technology and Research (A*STAR), National University Hospital (NUH), and Tan Tock Seng Hospital (TTSH).

Accurate

GASTROClear is a high performance test for early detection of gastric cancer. The test detected 87.5% of stage I gastric cancers and 89.5% of stage II gastric cancers in clinical validation1.

Complementary

GASTROClear is designed to be an adjunct test to complement upper GI endoscopy, the existing gold standard for gastric cancer diagnosis, for sensitive and cost-effective gastric cancer screening.

Minimally-invasive

GASTROClear is a liquid biopsy test that assesses gastric cancer risk by measuring 12 gastric cancer-associated microRNAs from a single draw of one tube (5 milliliters) of a patient's blood.

Actionable

GASTROClear is an actionable diagnostic test for cancer screening. It gives a quantitative risk score and classifies each patient into a risk group. Clear recommendations for follow-up actions are provided in test report to help doctors manage patients.

Validated

GASTROClear has been rigorously validated in large-scale clinical studies with over 5,000 patients from Singapore and Korea. The study has been published in Gut, a leading international journal of gastroenterology and hepatology1.

Setting standards

GASTROClear sets the standard for microRNA-based diagnostic tests as an exemplar used in drafting Singapore Standard 656, the world's first national standard for design, development and validation microRNA-based diagnostics2.

1 So JBYKapoor RZhu F, et al. Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population.

2 https://www.singaporestandardseshop.sg/Product/SSPdtDetail/952ba6cf-6c1e-4712-9719-07bd5ece3f09

GASTROClear

microRNA test

GASTROClear test can be ordered by healthcare providers through MiRXES partner diagnostic labs

Tan Tock Seng Hospital (TTSH)
Molecular Diagnostic Lab (MDL)

National University Hospital (NUH)
Molecular Diagnosis Centre (MDC)

ParkwayHealth Laboratory

Innovative Diagnostics

GASTROClear Order Information and Product Support

For clinical diagnostic labs and healthcare providers only.

The science and story

of GASTROClear

Interview with Prof. Yeoh Khay Guan, Lead Principal Investigator of the Singapore Gastric Cancer Consortium (SGCC), and Prof. Too Heng-Phon, Co-founder of MiRXES.

Play Video